Galectin‐1 targets brain endothelial cell changes, reduces vascular amyloid deposition and restores blood‐brain barrier (BBB) integrity in Alzheimer's Disease models
These novel findings position Gal1 as a pleiotropic modulator of AD pathology, with a focus on microvascular changes. Given the multifactorial nature of this pathology, Gal1-based strategies could target disease mechanisms at multiple levels.
Authors
- Soledad Gori (ORCID: https://orcid.org/0000-0002-9516-8003)
- Agustina Alaimo (ORCID: https://orcid.org/0000-0002-8070-9620)
- Jessica Presa (ORCID: https://orcid.org/0000-0002-7508-0055)
- Gabriel A. Rabinovich (ORCID: https://orcid.org/0000-0002-0947-8735)
- R Ramhorst
- Joaquín P. Merlo (ORCID: https://orcid.org/0000-0002-4587-5164)
- Juan Beauquis (ORCID: https://orcid.org/0000-0003-1404-5632)
- Carlos Pomilio
- Ellen Matzkin
- Flavia Saravia
- Mariano Soiza Reilly
- Montana Manselle
Institutions
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Universidad de Buenos Aires (AR)
- Instituto de Química y Fisicoquímica Biológicas (AR)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_107216
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 0.00